Intervention empagliflozin + metformin N = 765 patients with events n (%)
|
|
- Mabel Dean
- 5 years ago
- Views:
Transcription
1 Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in accordance with the German Social Code, Book Five (SGB V), section 35a from 5 February 2015 In its session on 5 February 2015, the Federal Joint Committee resolved to amend the Pharmaceutical Directive (AM-RL), version published 18 December 2008/22 January 2009 (Federal Gazette, number 49a of 31 March 2009), last amended on 22 January 2015 (Federal Gazette, AT B2) as follows: I. Appendix XII shall be amended in alphabetical order to include the active ingredient empagliflozin: Therapeutic indication: Jardiance is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as: Monotherapy When diet and exercise alone do not provide adequate glycaemic control in s for whom use of metformin is considered inappropriate due to intolerance. Add-on combination therapy In combination with other glucose lowering pharmaceuticals including insulin, when these, together with diet and (see sections 4.4, 4.5, and 5.1 for data currently available on various combinations). 1. Additional benefit of the pharmaceutical over appropriate comparator a) In monotherapy, when diet and exercise alone do not provide adequate glycaemic control in s for whom the use of metformin is considered inappropriate due to intolerance Appropriate comparator: a sulfonylurea (glibenclamide or ) Extent and probability of additional benefit of empagliflozin over a sulfonylurea (glibenclamide or ) An additional benefit has not been proved. b) In combination with other glucose-lowering medicinal products (except insulin), when these, together with diet and b1) In dual combination with metformin Appropriate comparator: metformin + a sulfonylurea (glibenclamide or ) (Please note: if metformin is inappropriate when used according to product information, human insulin is to be used as a treatment option)
2 Extent and probability of additional benefit of empagliflozin in combination with metformin over metformin and a sulfonylurea (glibenclamide or ): An additional benefit has not been proved. Study results according to endpoints (study ) 1 Symptomatic hypoglycaemia (PG 54 mg/dl) Symptomatic hypoglycaemia (54 mg/dl PG 70 mg/dl) Severe hypoglycaemia Intervention empagliflozin + metformin N = 765 s with events n (%) Control + metformin N = 780 s with events n (%) 5 (0.7) 62 (7.9) 0.08 [0.03; 0.20] < a 8 (1.0) 104 (13.3) 0.08 [0.04; 0.16] < a No relevant evaluation was available for this endpoint Renal and urinary disorders d 112 (14.6) 55 (7.1) 2.02 [1.50; 2.73] < a Diseases of the sexual organs and 91 (11.9) 46 (5.9) 1.95 mammary gland d [1.40; 2.73] < a Genital infections e 90 (11.8) 17 (2.2) 5.40 [3.25; 8.98] < Overall rate AE 661 (86.4) 673 (86.3) Intervention vs. control RR or Peto-OR [95% CI] p-value Mortality All-cause mortality 5 (0.7) 5 (0.6) POR 1.02 [0.29; 3.54] > a Morbidity MACE 12 (1.6) 16 (2.1) 0.76 [0.36; 1.61] a Cardiovascular death 1 (0.1) 4 (0.5) 0.25 [0.03; 2.28] a Non-fatal myocardial infarction 3 (0.4) 7 (0.9) POR 0.46 [0.13; 1.58] a Non-fatal stroke 9 (1.2) 7 (0.9) POR 1.31 [0.49; 3.51] a Change in MV at study end b in kg (SE) DM b [95% CI] p-value Body weight 3.12 (0.13) 1.34 (0.13) 4.46 [ 4.81; 4.10] < Medical condition (EQ-5D VAS) Health-related quality of life No applicable data Side effects No applicable data available c 1 Data from IQWiG benefit assessment A from 13 November 2014; study : RCT, direct comparison: 25 mg + metformin vs. + metformin (104 weeks).
3 Intervention empagliflozin + metformin N = 765 s with events n (%) Control + metformin N = 780 s with events n (%) Intervention vs. control RR or Peto-OR [95% CI] p-value Overall rate SAE 119 (15.6) 89 (11.4) 1.36 [1.06; 1.76] a Termination of treatment due to AE 39 (5.1) 34 (4.4) 1.17 [0.75; 1.83]; a IQWiG calculation, exact Fisher test. b Adjusted for baseline scores, HbA1c, kidney function (egfr), and geographical region. c Only analysis without replacement of missing scores available. Because the percentage of s not considered in the analysis was > 30%, the data are not shown. d Evaluation according to system organ class (MedDRA-SOC). e Evaluation (planned in advance) in accordance with MedDRA query developed by the pharmaceutical company. Abbreviations: egfr: estimated glomerular filtration rate; EQ-5D VAS: Euro-Qol-5D visual analog scale; CI: confidence interval; MACE: major adverse cardiovascular events; MedDRA: Medical Dictionary for Regulatory Activities; MV: mean value, DM: difference of means; N: number of s evaluated; n: number of s with events; PG: plasma glucose; POR: Peto odds ratio; RCT: randomized controlled trial; RR: relative risk; SE: standard error; SAE: serious adverse event; AE: adverse event; vs: versus b2) In dual combination with another glucose-lowering pharmaceutical other than metformin and insulin Appropriate comparator: + a sulfonylurea (glibenclamide or ) (Please note: if metformin is inappropriate when used according to product information, human insulin is to be used as a treatment option) Extent and probability of additional benefit of empagliflozin in combination with another glucose-lowering pharmaceutical (other than metformin and insulin) over metformin and a sulfonylurea (glibenclamide or ): An additional benefit has not been proved. c) In combination with at least two other glucose-lowering medicinal products when these, together with diet and Appropriate comparator: metformin + human insulin (Please note: therapy only with human insulin if metformin as used according to product information is insufficiently effective or not tolerated.) Extent and probability of additional benefit of empagliflozin in combination with at least two other glucoselowering pharmaceuticals over metformin and human insulin: An additional benefit has not been proved. d) In combination with insulin (with or without an oral anti-diabetic medication) Appropriate comparator: metformin + human insulin (Please note: therapy only with human insulin if metformin as used according to product information is insufficiently effective or not tolerated.) Extent and probability of additional benefit of empagliflozin in combination with insulin (with or without an oral anti-diabetic medication) over metformin and human insulin: An additional benefit has not been proved. 2. s and criteria for defining s eligible for treatment a) In monotherapy, when diet and exercise alone do not provide adequate glycaemic control in s for whom the use of metformin is considered inappropriate due to intolerance Number: approx. 221,400 s b) In combination with other glucose-lowering medicinal products (except insulin), when these, together with diet and b1) In dual combination with metformin Number: approx. 468,700 s
4 b2) In dual combination with another glucose-lowering pharmaceutical other than metformin and insulin Number: approx. 35,900 s (dual combination with a sulfonylurea) c) In combination with at least two other glucose-lowering medicinal products when these, together with diet and Number: approx. 77,400 s d) In combination with insulin (with or without an oral anti-diabetic medication) Number: approx. 450, ,000 s 3. Requirements for quality-assured administration The specifications outlined in the product information are to be followed. The European Medicines Agency (EMA), the European regulatory authority, provides the product information for Jardiance (active ingredient: empagliflozin) at the following public link (last accessed: 13 January 2014): _Product_Information/human/002677/WC pdf 4. Costs of treatment a) In monotherapy, when diet and exercise alone do not provide adequate glycaemic control in s for whom the use of metformin is considered inappropriate due to intolerance Duration of treatment: Pharmaceutical evaluated (empagliflozin) treatment days per per year ongoing Appropriate comparator (sulfonylurea [glibenclamide or ]) Glibenclamide or ongoing ongoing Consumption: Strength Quantity per pack (tablets) 2 Average annual consumption (tablets) Pharmaceutical evaluated (empagliflozin) 10 mg 25 mg Appropriate comparator (sulfonylurea [glibenclamide or ]) Glibenclamide 3 or 3.5 mg 1 6 mg ,095 Costs: Cost of pharmaceutical: Pharmaceutical evaluated (empagliflozin) 10 mg or empagliflozin 25 mg [ ; ] [ ; ] Largest pack. Calculation is based on a strength of 3.5 mg. Dosage according to product information mg. Rebate in accordance with SGB V, section 130. Rebate in accordance with SGB V, section 130a.
5 Appropriate comparator (sulfonylurea [glibenclamide or ]) Glibenclamide 6 or [ ; ] [ ; ] Lauer-Taxe, effective: 1 January 2015 Costs for additional, necessary SHI benefits: none Annual treatment costs: Pharmaceutical evaluated (empagliflozin) Annual treatment costs per Appropriate comparator (sulfonylurea [glibenclamide or ]) Glibenclamide or b) In combination with other glucose-lowering medicinal products (except insulin), when these, together with diet and b1) In dual combination with metformin Duration of treatment: per year Pharmaceutical evaluated (empagliflozin in combination with metformin) treatment days per per year ongoing ongoing Glibenclamide or ongoing ongoing ongoing Consumption: Strength Quantity per pack (tablets) 2 Pharmaceutical evaluated (empagliflozin in combination with metformin) 10 mg 25 mg Average annual consumption (tablets) 7 1,000 mg 1,095 Glibenclamide 3 or 3.5 mg 1 6 mg , ,000 mg 1, Reference price. Calculation is based on a strength of 1,000 mg. Dosage according to product information 1,000 to 3,000 mg.
6 Costs: Cost of pharmaceutical: Pharmaceutical evaluated (empagliflozin in combination with metformin) 10 mg or [ ; ] empagliflozin 25 mg [ ; ] Glibenclamide 6 or [ ; ] [ ; ] Lauer-Taxe, effective: 1 January 2015 Costs for additional, necessary SHI benefits: none Annual treatment costs: Annual treatment costs per Pharmaceutical evaluated (empagliflozin in combination with metformin) + metformin Glibenclamide + metformin or + metformin b2) In dual combination with another glucose-lowering pharmaceutical other than metformin and insulin Duration of treatment: treatment days per per year Pharmaceutical evaluated (empagliflozin in combination with another glucose-lowering pharmaceutical besides metformin and insulin) 8 1 daily ongoing Glibenclamide or ongoing Glimepiride ongoing Glibenclamide or ongoing ongoing ongoing 8 The combination with a sulfonylurea is shown as an example of a combination therapy with another glucose-lowering pharmaceutical besides metformin and insulin.
7 Consumption: Strength Quantity per pack (tablets) 2 Average annual consumption (tablets) Pharmaceutical evaluated (empagliflozin in combination with another glucose-lowering pharmaceutical besides metformin and insulin) 8 10 mg 25 mg Glibenclamide 3 or 3.5 mg 1 6 mg ,095 Glibenclamide 3 or 3.5 mg 1 6 mg , ,000 mg 1,095 Costs: Cost of pharmaceutical: Pharmaceutical evaluated (empagliflozin in combination with another glucose-lowering pharmaceutical besides metformin and insulin) 8 10 mg or [ ; ] empagliflozin 25 mg [ ; ] Glibenclamide 6 or [ ; ] [ ; ] Glibenclamide 6 or [ ; ] [ ; ] Lauer-Taxe, effective: 1 January 2015 Costs for additional, necessary SHI benefits: none Annual treatment costs: Annual treatment costs per Pharmaceutical evaluated (empagliflozin in combination with another glucose-lowering pharmaceutical besides metformin and insulin) 8 + glibenclamide or empagliflozin Glibenclamide + metformin or + metformin
8 c) In combination with at least two other glucose-lowering medicinal products when these, together with diet and Duration of treatment: treatment days per per year Pharmaceutical evaluated (empagliflozin as a combination therapy with at least two other glucose-lowering pharmaceuticals) 9 ongoing Glibenclamide or ongoing Glimepiride ongoing ongoing Appropriate comparator (metformin + human insulin; therapy only with human insulin if metformin is Human insulin (NPH insulin) ongoing ongoing Conventional insulin therapy (combination insulin) ongoing Consumption: Strength Quantity per pack (tablets) 2 Average annual consumption (tablets) Pharmaceutical evaluated (empagliflozin as a combination therapy with at least two other glucose-lowering pharmaceuticals) 9 10 mg 25 mg Glibenclamide 3 or 3.5 mg , mg 7 1,000 mg 1,095 Appropriate comparator (metformin + human insulin; therapy only with human insulin if metformin is insufficiently effective or not tolerated) Human insulin (NPH insulin) 10 IU/ml 3,000 IU 13,797 27,594 IU 1,000 mg 1,095 Conventional insulin therapy (combination insulin) 10 IU/ml 3,000 IU 13,797 27,594 IU Costs: Cost of pharmaceutical: Pharmaceutical evaluated (empagliflozin as a combination therapy with at least two other glucose-lowering pharmaceuticals) 9 10 mg oder empagliflozin 25 mg [ ; ] [ ; ] 9 10 The combination with a sulfonylurea and metformin is shown as an example of combination therapy with at least two other glucose-lowering medicinal products. Average insulin need: IU/kg BW/day; reference body weight: 75.6 kg BW ("microcensus 2009").
9 Glibenclamide 6 or [ ; ] [ ; ] Appropriate comparator (metformin + human insulin; therapy only with human insulin if metformin is Human insulin (NPH insulin) [ ; ] Conventional insulin therapy (combination insulin) [ ; ] Lauer-Taxe, effective: 1 January 2015 Costs for additional, necessary statutory health insurance (SHI) benefits: Additional necessary SHI benefits Cost/pack 11 Consumption/ Designation Number/day year Cost/year Appropriate comparator human Blood sugar strips , insulin plus metformin Lancets , (or therapy only with human insulin) Single-use needles Annual treatment costs: Annual treatment costs per Pharmaceutical evaluated (empagliflozin as a combination therapy with at least two other glucose-lowering pharmaceuticals) 9 + metformin + glibenclamide or empagliflozin + metformin , Appropriate comparator (metformin + human insulin; therapy only with human insulin if metformin is Human insulin (NPH insulin) + metformin Conventional insulin therapy (combination insulin) Costs for additional, necessary SHI benefits: Blood sugar test strips Lancets Single-use needles d) In combination with insulin (with or without an oral anti-diabetic medication) Duration of treatment: treatment days per per year Pharmaceutical evaluated (empagliflozin as a combination therapy with insulin [with or without an oral anti-diabetic medication]) 12 ongoing test strips/pack = 50; lancets/pack = 200; single-use needles/pack = ; least expensive pack according to "Lauer- Taxe"; effective: 1 January is named as an example of an additional anti-diabetic medication.
10 Human insulin (NPH insulin) ongoing ongoing Appropriate comparator (human insulin with metformin; therapy only with human insulin if metformin is Human insulin (NPH insulin) ongoing ongoing Conventional insulin therapy ongoing (combination insulin) 10 Consumption: Strength Quantity per pack (tablets) 2 treatment days per per Average annual consumption (tablets) Pharmaceutical evaluated (empagliflozin as a combination therapy with insulin [with or without an oral anti-diabetic medication]) mg 25 mg Human insulin (NPH insulin) 10 IU/ml 3,000 IU 13,797 27,594 IU 7 1,000 mg 1,095 Appropriate comparator (human insulin with metformin; therapy only with human insulin if metformin is Human insulin (NPH insulin) 10 IU/ml 3,000 IU 13,797 27,594 IU 1,000 mg 1,095 Conventional insulin therapy IU/ml 3,000 IU 13,797 27,594 IU (combination insulin) 10 Costs: Cost of pharmaceutical: Pharmaceutical evaluated (empagliflozin as a combination therapy with insulin [with or without an oral anti-diabetic medication]) mg or [ ; ] 25 mg [ ; ] Human insulin (NPH insulin) [ ; ] Appropriate comparator (human insulin with metformin; therapy only with human insulin if metformin is Human insulin (NPH insulin) [ ; ]
11 Conventional insulin therapy (combination insulin) 6 [ ; ] Lauer-Taxe, effective: 1 January 2015 Costs for additional, necessary SHI benefits: none Annual treatment costs: Annual treatment costs per Pharmaceutical evaluated empagliflozin as a combination therapy with insulin (with or without an oral anti-diabetic medication) 12 + human insulin (NPH insulin) or empagliflozin + human insulin (NPH insulin) + metformin 1, , , , Appropriate comparator human insulin with metformin; therapy only with human insulin if metformin is insufficiently effective or not tolerated Human insulin (NPH insulin) + metformin Conventional insulin therapy (combination insulin) II. This resolution takes effect on the day of its publication in the internet on the website of the Federal Joint Committee on 5 February The justification for this resolution will be published on the websites of the Federal Joint Committee at Berlin, 5 February 2015 The Federal Joint Committee in accordance with SGB V, section 91 The Chair Hecken
Number of treatments per patient. Designation of therapy Strength Dose/day Number/amount per pack 1
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationongoing Insulin degludec/liraglutid 1 daily ongoing x daily
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationMortality. p =
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationPonatinib in chronic myeloid leukaemia (CML) 2
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationfrom 20 February 2014
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII - Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationEffect estimates [95% CI] BOC+PegIFN/RBV vs. PegIFN/RBV
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationAclidinium bromide/formoterol Endpoint category. RR Endpoint. [95% CI 2 ] Study. with event
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationfrom 21 June 2012 Mortality Overall mortality 1.6% vs. 0% Morbidity Absolute change in degree of spasticity (NRS score) [-1.29; -0.
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationFrom 19 February 2015
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment pharmaceuticals with new active ingredients, in accordance
More informationfrom 29 March 2012 Effect estimates [95% CI] Telaprevir + PegIFN/RBV vs. PegIFN/RBV
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationd) Patients with moderately to severely active Crohn s disease who have had an inadequate response with, lost
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More information1 x weekly 50 mg. Consumption:
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationDeaths Patients with events (%) 0 vs. 0 n.r.
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationEmpagliflozin (type 2 diabetes mellitus)
IQWiG Reports Commission o. A16-46 Empagliflozin (type 2 diabetes mellitus) Addendum to Commission A16-12 1 Addendum Commission:A16-46 Version: 1.0 Status: 29 July 2016 1 Translation of addendum A16-46
More informationLinagliptin Renewed benefit assessment according to 35a Paragraph 5b Social Code Book V 1
IQWiG Reports Commission No. A12-11 Linagliptin Renewed benefit assessment according to 35a Paragraph 5b Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment ( Linagliptin
More informationAddendum to Commission A14-12 (canagliflozin) 1
IQWiG Reports Commission No. A14-24 Addendum to Commission A14-12 (canagliflozin) 1 Addendum Commission:A14-24 Version: 1.0 Status: 4 August 2014 1 Translation of addendum A14-24 Addendum zum Auftrag A14-12
More informationIQWiG Reports Commission No. A Dulaglutide
IQWiG Reports Commission No. A15-07 Dulaglutide Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.7 of the dossier assessment Dulaglutid Nutzenbewertung
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationEmpagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study
Empagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study POSITION STATEMENT: Clinicians should continue to follow MHRA advice and NICE technology appraisal guidance
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 17 December 2014 JARDIANCE 10 mg, film-coated tablet B/30 tablets (CIP: 34009 278 928 5 1) JARDIANCE 25 mg, film-coated
More informationUK launch of once-daily tablet from Janssen provides new option to improve blood glucose control for thousands of people with Type 2 diabetes 1
PRESS RELEASE 24 th February, 2014 UK launch of once-daily tablet from Janssen provides new option to improve blood glucose control for thousands of people with Type 2 diabetes 1 London, 24 February 2014
More informationTechnology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418
Dapagliflozin in triple therapy for treating type 2 diabetes Technology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418 NICE 2018. All rights reserved. Subject to Notice of rights
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationLimitations of Use: Glumetza is not used for the treatment of type 1 diabetes or ketoacidosis (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.20 Subject: Glumetza Page: 1 of 5 Last Review Date: March 18, 2016 Glumetza Description Glumetza (extended-release
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationSaxagliptin/metformin Benefit assessment according to 35a Social Code Book V 1
IQWiG Reports Commission No. A12-16 Saxagliptin/metformin Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Saxagliptin/Metformin
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationSacubitril/valsartan
IQWiG Reports Commission No. A15-60 Sacubitril/valsartan Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Sacubitril/Valsartan
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes
National Institute for Health and Care Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes Response to consultee and commentator
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationCanagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin in combination therapy for treating type 2 Issued: June 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce
More informationEuropean Medicines Agency decision
EMA/741983/2016 European Medicines Agency decision P/0324/2016 of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta), (EMEA-000498-PIP01-08-M06)
More informationEuropean Medicines Agency decision
EMA/776083/2014 European Medicines Agency decision P/0001/2015 of 7 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta) (EMEA-000498-PIP01-08-M04)
More informationDPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes
THERAPY REVIEW DPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes STEVE CHAPLIN SPL DPP-4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixeddose
More informationempagliflozin 10mg and 25mg tablet (Jardiance ) SMC No. (993/14) Boehringer Ingelheim / Eli Lilly
empagliflozin 10mg and 25mg tablet (Jardiance ) SMC No. (993/14) Boehringer Ingelheim / Eli Lilly 05 September 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationGuideline for antihyperglycaemic therapy in adults with type 2 diabetes
Guideline for antihyperglycaemic therapy in adults with type 2 diabetes Version Control Version Number Date Amendments made 1 January 2018 1.1 February 2018 Amended to reflect updated SPC advice for sitagliptin
More informationTechnology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta288
Dapagliflozin in combination therapy for treating type 2 diabetes Technology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta288 NICE 2018. All rights reserved. Subject to Notice of rights
More informationJARDIAMET. (empagliflozin and metformin hydrochloride) 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, 12.
JARDIAMET (empagliflozin and metformin hydrochloride) 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, 12.5 mg/1000 mg NAME OF THE MEDICINE JARDIAMET contains two oral antihyperglycaemic
More informationCollaborative Practice Agreement
Collaborative Practice Agreement [community pharmacy name] [address] [phone number] [physician practice] [address] [phone number] Effective: [date] Expiration: [date] 1 Table of Contents 1.0 Introduction...4
More informationTechnology appraisal guidance Published: 27 March 2019 nice.org.uk/guidance/ta572
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes Technology appraisal guidance Published: 27 March 2019 nice.org.uk/guidance/ta572 NICE 2019. All rights reserved. Subject to
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.19 Subject: SGLT2 Inhibitors Page: 1 of 6 Last Review Date: September 15, 2016 SGLT2 Inhibitors Description
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 VELMETIA 50 mg/850 mg, film-coated tablets B/56 (CIP code: 386 778-0) VELMETIA 50 mg/1 000 mg, film-coated
More informationSitagliptin/metformin Benefit assessment according to 35a Social Code Book V 1
IQWiG Reports Commission No. A13-03 Sitagliptin/metformin Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Sitagliptin/Metformin
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationIxekizumab (plaque psoriasis)
IQWiG Reports Commission No. A17-07 Ixekizumab (plaque psoriasis) Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Ixekizumab
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationWHO Guidelines for Management of Diabetes in Low Resource Settings
WHO Guidelines for Management of Diabetes in Low Resource Settings 24 th November, 2018 Dr. Alok Shetty K Senior Resident Department of Medicine St. John s Medical College & Hospital WHO vs ADA-EASD Revisiting
More informationInvolvement of people affected
Involvement of people affected in the dossier assessment 1 1 Translation of the document Beteiligung von Betroffenen bei der Dossierbewertung (Version 1.1; Status: 28 July 2017). Please note: This translation
More informationEmpagliflozin/metformin
IQWiG Reports Commission No. A16-13 Empagliflozin/metformin Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Empagliflozin/Metformin
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationLilly Diabetes: Pipeline Update
Lilly Diabetes: Pipeline Update June 16, 2014 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ
More informationHave you seen a patient like Elaine *?
(linagliptin) 5mg tablets Have you seen a patient like Elaine *? *Hypothetical patient profile Elaine * : 60 years old Housewife *Hypothetical patient profile ELAINE*: T2D Patient with early signs of kidney
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine. According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationEli Lilly and Company
Eli Lilly and Company Strategic Diabetes Alliance with Boehringer Ingelheim January 11 th, 2011 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationsitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationHave you seen a patient like Carol *?
(linagliptin) 5mg tablets Have you seen a patient like Carol *? *Hypothetical patient profile Carol * : 70 years old Retired schoolteacher *Hypothetical patient profile CAROL*: T2D patient with moderate
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationSafinamide (Addendum to Commission A15-18) 1
IQWiG Reports Commission No. A15-41 Safinamide (Addendum to Commission A15-18) 1 Addendum Commission:A15-41 Version: 1.1 Status: 29 October 2015 1 Translation of addendum A15-41 Safinamid (Addendum zum
More informationdapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca
dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 September 2012 (Issued 07 December 2012) The Scottish Medicines Consortium (SMC) has completed
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationSponsor: Sanofi Drug substance(s): Lantus /insulin glargine. Study Identifiers: U , NCT Study code: LANTUL07225
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.19 Subject: SGLT2 Inhibitors Page: 1 of 5 Last Review Date: December 3, 2015 SGLT2 Inhibitors Description
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Dapagliflozin for the treatment of type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Dapagliflozin for the treatment of type 2 diabetes Submitted by Bristol-Myers Squibb and AstraZeneca Single technology appraisal (STA) 17 th July 2012
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationMANAGEMENT OF TYPE 2 DIABETES
MANAGEMENT OF TYPE 2 DIABETES 3 Month trial of lifestyle changes. Refer to DESMOND structured education programme. Set glycaemic target HbA1c < 7.0% (53mmol/mol) or individualised If HbA1c > 53mmol/mol
More informationEuropean Medicines Agency decision
EMA/43440/2014 European Medicines Agency decision P/0046/2014 of 7 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (EMEA- 000498-PIP01-08-M02)
More informationPeer Review Report. [long acting insulin analogues glargine and detemir]
21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report [long acting insulin analogues glargine and detemir] (1) Does the application adequately address the issue of the public
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More information1. Pharmacokinetics. When is steady state achieved? Steady-state was reached after 4 to 5 days of once-daily dosing with Sulisent 100 mg to 300mg.
1. Pharmacokinetics How is Sulisent metabolized? Sulisent has a novel mechanism of action that targets the kidneys and allows for excess glucose excretion resulting in urinary calorie loss. Sulisent is
More informationScottish Medicines Consortium
Scottish Medicines Consortium saxagliptin, 5mg film-coated tablet (Onglyza ) No. (603/10) Bristol-Myers Squibb Pharmaceuticals Ltd 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationIQWiG Reports Commission No. A05-05C. Executive Summary
IQWiG Reports Commission No. A05-05C Glinides in the treatment of diabetes mellitus type 2 1 Executive Summary 1 Translation of the executive summary of the final report Glinide zur Behandlung des Diabetes
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: November 30, 2018 SGLT2 Inhibitors Description
More informationSanofi Announces Results of ORIGIN, the World s Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes
PRESS RELEASE Sanofi Announces Results of ORIGIN, the World s Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes Dublin, Ireland (15 June 2012) Sanofi presented results
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationEuropean Medicines Agency decision
EMA/155875/2015 European Medicines Agency decision P/0062/2015 of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia), (EMEA-000470-PIP01-08-M09)
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationWhat was the study about?
Dear Reader, Pharmaceutical companies (sponsors) plan and conduct clinical studies to test medicines. Afterwards, they write study reports. A study report describes how a study was done and what the results
More informationEuropean Medicines Agency decision
EMA/848760/2017 European Medicines Agency decision P/0033/2018 of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia), (EMEA-000470-PIP01-08-M10)
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationSafety, Tolerability, Pharmacokinetics,and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Safety, Tolerability, Pharmacokinetics,and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus Journal Club (May 2013) Sara Al-Sharhan, Pharm D intern-
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Policy: Sodium-Glucose Co-Transpter 2 (SGLT2) Inhibits Reference Number: TCHP.PHAR.182 Effective Date: 07.01.18 Last Review Date: 04.13.18 Line of Business: Oregon Health Plan Revision Log See Imptant
More informationIndications and labelling; general aspects. EMA-Payer Community meeting Sept 19th, 2017 Kristina Dunder, CHMP member
Indications and labelling; general aspects EMA-Payer Community meeting Sept 19th, 2017 Kristina Dunder, CHMP member 1 Scope; Smpc Try to reflect current regulatory thinking on indications and labelling
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationMedicines Optimisation Team Standard Operating procedure for Alogliptin Audit:
Medicines Optimisation Team Standard Operating procedure for Alogliptin Audit: To review type 2 diabetic patients prescribed dipedtidylpeptidase-4 (DPP-4) inhibitors (linagliptin (Trajenta, saxagliptin
More informationExecutive Summary. Evaluation of the therapeutic benefits and harms of exenatide 1. IQWiG Reports - Commission No. A05-23
IQWiG Reports - Commission No. A05-23 Evaluation of the therapeutic benefits and harms of exenatide 1 Executive Summary 1 Translation of the executive summary of the final report Bewertung des therapeutischen
More informationCost Effectiveness of canagliflozin (Invokana )
Cost Effectiveness of canagliflozin (Invokana ) for adults with type 2 diabetes mellitus to improve glycaemic control as monotherapy or add-on therapy with other anti-hyperglycaemic agents including insulin,
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More information